By Ryan McGuire,
Head of Research

The MSL role should be an easy to define. But if this is truly the case, why does the pharmaceutical industry use so many different titles used to describe the function? Besides medical science liaisons, there are also regional medical liaisons, clinical science liaisons and regional scientific liaisons.  Independent of their actual title, they all perform the same essential duties — bridging the gap between pharmaceutical companies and the medical community.  On the surface, the definition of an MSL is quite logical; however, once you take into account all of the typical responsibilities, the MSL role begins to look quite complex. Continue reading “What’s In A Name? How the Functional Title Encompasses the MSL Role” »


By Jacob Presson,
Senior Research Analyst

If anything could be said about the ancient Romans, aside from their insatiable drive for conquest and glory, it was their proclivity for documenting everything that happened around them.  The fact that we know so much about the Romans comes down to the sheer level of documentation that survives from their time.  When pharmaceutical companies are looking at their own documentation priorities, preserving regulatory knowledge and the associated protocols should be close to the top of the list. Continue reading “Document Like the Romans: Maintaining Regulatory Knowledge” »


By Natalie DeMasi,
Director of Research

Orchestrating lifecycle management (LCM) techniques can be a complicated, and — as with any strategic operation — different players contribute to the process over time.  In the life sciences industry, companies optimize lifecycle management by involving the right functions at the right time throughout the product’s development and commercialization.  For example, R&D is far more important in the early years of product development.  On the other hand, market access plays a major role closer to product launch. Continue reading “Coordinating Lifecycle Management Techniques: Involving the Right Functions at the Right Time” »


By Ryan McGuire,
Head of Research

A new study from CEI reveals that oncologists receive the highest average clinical trial compensation per patient visit.  Surveyed clinical trial managers report that principle investigators earn an average of $599 per patient visit.  This owes much to the complexity of procedures required in oncology trials and the long hours that trial staff spend with ailing patients. Continue reading “Oncology is the Top Disease Area for Clinical Trial Compensation” »


By Sarah Ray,
Senior Research Analyst

Medical advisory boards take a number of forms across life science companies’ clinical, marketing and market access teams.  Although recent legislature limits how companies interact with the physicians and other key opinion leaders (KOLs) who most commonly staff these boards they do not decrease the importance of these institutions. When leveraged appropriately, medical advisory boards — which combine members’ expertise and unique insights — are a huge asset to the industry as a whole. Continue reading “Medical Advisory Boards: Refreshing Companies’ Clinical, Marketing and Market Access Strategies, One Meeting at a Time” »


By David Richardson,
Director of Research

Let’s face it, Google makes us smarter.  Well…not really.  But it certainly gives us a window into all kinds of information that used to be held only by professionals.  The healthcare industry has certainly seen an uptick in customer knowledge over the last several years.  Patients and healthcare providers alike can now use their search engines to do fairly deep dives into diseases state information and treatment options.  This access has a big impact on pharmaceutical call center management teams.  Patients and health care providers can answer many of the questions that they formerly asked of medical information groups with quick internet search.  Medical information teams are also receiving additional, more complicated questions than in the past. Continue reading “Pharmaceutical Call Center Management: Evolve to Respond to Better Informed Customers” »

For a product to succeed in today’s commercial landscape, pharma companies must be able to prove its value during regulatory and market access discussions.  Pharmaceutical PRO metrics offer both clinical teams and regulatory agencies a complete picture of a drug’s effects and its’ future success.  While clinical data alone can determine whether or not a drug produces the necessary medical effects, PROs go a step further.  Patient-reported outcomes depict how well the end-users are able to comply with the product’s dosing instructions and if they can handle any side effects.  The patient’s depiction of their adherence and their experiences add value to product dossiers during regulatory approval and reimbursement initiatives. Continue reading “Embracing Pharmaceutical PRO Metrics to Support Regulatory Approval and Product Reimbursement” »


By Natalie DeMasi, Research Analyst

After being untouchable for decades, US biologics companies are finally facing biosimilar competition.  Well, sort of.  Cutting Edge Information’s report on counter-generics strategies found that the high cost of biosimilar production will not allow companies to price biosimilars substantially below that of the original product – meaning they may not have the same market impact that a typical generic would.  Instead, biobetters may be the next biggest thing to rock the biologics world. Continue reading “Biosimilars, Biobetters and Captain America: The Future of Biosimilars in a Future World of Biobetters” »


By Victoria Cavicchi,
Research Analyst

Within the life sciences industry, medical publications groups are tasked with a critical responsibility: sharing company findings and new scientific brand support details with the healthcare community.  To ensure that these key medical communications groups are working efficiently, companies should provide them with the resources needed to meet demands.  Whether teams are responsible for 5 or 500 publications per year, companies should right-size the staffing and budgets allocated to these efforts.  They should also consider company structure. Cutting Edge Information’s recent study on medical publications departments highlights how top-performing pharmaceutical and device organizations resource and measure performance across various high- and low-output team structures. Continue reading “Are You Ready to Optimize Your Medical Publications Department?” »


By Jacob Presson,
Senior Research Analyst

Building and managing payer relationships doesn’t always receive the same level of dedicated attention as that of KOL relationships.  However, at the end of the day, nurturing these relationship types can have a similar level of impact.  A product’s pricing can be largely dependent on the quality of the relationship cultivated between the managed markets account manager and their contact within the insurer or hospital. Continue reading “Three Key Principles in Managing Payer Relationships” »